Enhanced Confidence in the Safety and Efficacy of CRISPR/Cas9 Gene Editing

Current approaches to characterizing CRISPR/Cas9-based cell and gene therapy candidates may miss off-target edits and correlated gene expression changes. Read our perspective on how emerging single-cell multiomics technologies put more comprehensive data in researchers' hands.

In this white paper, you'll read about:

  • The range of on-target and off-target genomic and transcriptomic changes possible with CRISPR/Cas9 gene editing
  • Why single-cell multiomic analysis is necessary to characterize and validate CRISPR/Cas9 therapeutic candidates
  • Tools that make it possible to precisely, sensitively detect insertions, deletions, substitutions, larger genomic alterations, alternative splicing events, and altered gene expression across the entire genome – and attribute these variants to individual cells.
Cells Explored. Answers Revealed.
By sharing your email address with us, you agree to receive occasional emails from BioSkryb Genomics, Inc. You can unsubscribe at any time.

Schedule a consultation